Skip to main content

Table 1 Summary of estimated radiobiological parameters

From: Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters

Cancer type \(T_{{\text{t}}}\) (days) \(T_{{\text{p}}}\) (days) \(T_{{\text{k}}}\) (d) \(\alpha\) (Gy−1) \(\alpha {/}\beta\) (Gy)
Breast 49 124 23 0.009 5.00
PNET 47 166 22 0.009 11.2
Adrenocortical carcinoma 49 136 9.0 0.005 4.21
CRC 53 170 26 0.005 49.8
Cholangiocarcinoma 42 200 41 0.015 1.00
CRC 42 108 2.0 0.006 5.83
CRC 49 180 29 0.008 4.00
Rectal adenocarcinoma 46 300 27 0.200 5.91
Cholangiocarcinoma 48 348 48 0.100 1.53
CRC 47 87.0 10 0.010 6.45
Cholangiocarcinoma 47 59.0 1.0 0.001 5.98
Cholangiocarcinoma 48 336 23 0.050 1.00
Sigmoid adenocarcinoma 77 232 27 0.200 6.67
Breast 55 180 55 0.080 1.00
Prostate 56 250 56 0.100 2.00
CRC 56 97.0 50 0.030 4.29
PNET 23 134 49 1.000 2.20
PDAC 49 180 49 0.300 1.00
SBNET 59 300 59 0.800 8.89
Mesothelioma 56 157 39 0.010 8.13
PNET 48 200 48 0.124 12.4
HCC 50 90.0 10 0.003 2.78
Oesophageal 47 200 46 0.050 1.25
SBNET 54 86.0 13 0.022 11.1
NEC 41 87.0 1.0 0.028 1.40
  1. \(T_{{\text{t}}}\), treatment time; \(T_{{\text{p}}}\), cell repopulation time; \(T_{{\text{k}}}\), kick-off time; PNET pancreatic neuroendocrine tumours, CRC colorectal cancer, PDAC pancreatic ductal adenocarcinoma, SBNET small bowel neuroendocrine tumours, HCC hepatocellular carcinoma, NEC neuroendocrine carcinoma.